Genome-wide CRISPR/Cas9 screens represent a powerful approach to study mechanisms of drug action and resistance. Cereblon modulating agents (CMs) have recently emerged as candidates for therapeutic intervention in primary effusion lymphoma (PEL), a highly aggressive cancer caused by Kaposi's sarcoma-associated herpesvirus. CMs bind to cereblon (CRBN), the substrate receptor of the cullin-RING type E3 ubiquitin ligase CRL4 CRBN , and thereby trigger the acquisition and proteasomal degradation of neosubstrates. Downstream mechanisms of CM toxicity are incompletely understood, however. To identify novel CM effectors and mechanisms of CM resistance, we performed positive selection CRISPR screens using three CMs with increasing toxicity in PEL: lenalidomide (LEN), pomalidomide (POM), and CC-122.
Introduction

Primary effusion lymphoma (PEL) is a non-Hodgkin B cell lymphoma (NHL) caused by
Kaposi's Sarcoma-associated Herpesvirus (KSHV) 1, 2 . PEL most commonly arises in HIV infected individuals, where it comprises ~4% of HIV-related NHLs 3 . PEL carries a poor prognosis, despite chemotherapy and anti-retrovirals 4, 5 . Recent work by us and others suggests that cereblon modulators (CMs), including the immunomodulatory drugs (IMiDs) lenalidomide (LEN) and pomalidomide (POM), may present a promising treatment strategy in PEL 6, 7 . LEN and POM are used in multiple myeloma (MM), as frontline therapy or upon relapse from LEN, respectively. Despite substantial efficacy of IMiDs in MM, patients commonly relapse. LEN is also effective in myelodysplastic syndrome with deletion of chromosome 5q [del(5q) MDS]. CC-122 is a fourth generation CM currently under pre-clinical investigation in diffuse large B cell lymphoma (DLBCL) 8 .
The molecular target of CMs is cereblon (encoded by CRBN), a substrate receptor of the cullin-RING type E3 ubiquitin ligase CRL4 CRBN 9 .
The covalent conjugation of ubiquitin (Ub) to target proteins is mediated by an enzymatic cascade that involves an E1 Ub activating enzyme, E2 Ub conjugating enzyme, and E3 Ub ligase, which attaches Ub to lysine (K) residues of protein substrates or Ub itself 10 . K48-linked Ub chains of four or more moieties canonically target substrates for degradation by the 26S proteasome. The modular cullin-RING E3 Ub ligases (CRLs) are comprised of one of seven cullin family scaffold proteins (CUL1, 2, 3, 4A, 4B, 5, or 7), which recruits a RING family protein with E3 ubiquitin ligase function and a substrate recognition module 11, 12 . The CRL4 complex specifically consists of cullin4A (CUL4A) or cullin4B (CUL4B), the RING protein RBX1, the adaptor protein DDB1 (damaged DNA binding 1), and one of several substrate receptors, including CRBN (Fig. 1A ) 9, 13, 14 . CRLs are regulated by dynamic modification of the cullin subunit with the ubiquitin-like modifier Nedd8 11, 12, 15, 16 . Like Ub, Nedd8 requires the sequential action of Nedd8-specific E1, E2 and E3 enzymes. Nedd8-modification of cullins is required for E3 ligase activity, by exposing RBX1 and thereby positioning the associated E2 enzyme in proximity of substrates 16 . Conversely, deneddylation of cullins is required for the exchange of the substrate receptor module 17, 18 . Cullin deneddylation 4 is mediated by the multisubunit COP9 signalosome (CSN) 19, 20 . Thus, cullin Nedd8-modification is highly dynamic, with neddylation required for E3 ligase activity and deneddylation required for substrate receptor exchange.
CMs bind to CRBN within the substrate recognition surface and thereby enable acquisition of neosubstrates, resulting in their polyubiquitination and proteasomal degradation [21] [22] [23] [24] [25] [26] . In multiple myeloma, CM-induced degradation of neosubstrates IKZF1 and IKZF3 and the subsequent downregulation of their transcriptional target IRF4 is thought be a major trigger of CM toxicity 21, 22 . Degradation of the neosubstrate CK1a, which is preferentially targeted by LEN, is thought to explain the efficacy of LEN in del(5q) MDS 27 . Recently, CMs have been shown to induce efficient cell death in PEL cell lines 6, 7 and LEN is currently part of a clinical trial in PEL (ClinicalTrials.gov Identifier:
NCT02911142). As in multiple myeloma 28 , the transcription factor IRF4 is a highly essential survival gene in PEL cells and its expression is reduced upon treatment with CMs 6, 7, 29 . Surprisingly, however, in this setting, downregulation of IRF4 and CM toxicity were independent of IKZF1 and/or IKZF3 7 . In PEL cell lines, CK1a is furthermore commonly essential and its degradation represents an IRF4-independent arm of CM toxicity 7 . The individual or combined re-expression of CK1a and IRF4 significantly, but incompletely, rescued PEL cell lines from CM-induced cell death, suggesting that additional mechanisms of CM action exist in PEL. Thus, further mechanistic investigation of CM toxicity in this and other cell types is warranted.
Genome-wide CRISPR screens represent a powerful tool to probe for genes whose inactivation confers drug resistance 30, 31 . In order to identify CM effectors, we applied this unbiased screening approach to identify genes whose inactivation confers resistance to LEN, POM, or CC-122 in PEL cells. Our results suggest that decreased CRL4 CRBN activity is the dominant pathway to resistance and identify several novel regulators of CRL4 CRBN . We validate the E2 enzyme UBE2G1 and the Nedd8-specific protease SENP8 as genes whose inactivation can confer resistance to LEN and/or POM. Inactivation of SENP8 indirectly increased the levels of unneddylated CUL4A/B, which interferes with LEN toxicity in a dominant negative manner.
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Methods
Cell lines and reagents
All parental cell lines were maintained as described recently 29 . Lenalidomide was from
Cayman Chemicals (Ann Arbor, MI) and pomalidomide and CC-122 were from Selleck Chemicals (Houston, TX). All compounds were dissolved in DMSO (Sigma-Aldrich, St.
Louis, MO). Lentiviruses were prepared as described previously and functionally titrated 29 . Generation and validation of clonal Cas9-expressing BC-3 and BCBL-1 cells were described 29 . Clonal BC-3 CRBN KO cells were described previously 7 . The lentiviral Brunello CRISPR KO library was obtained from Addgene (Cambridge, MA)
32
.
Genome-wide CRISPR screens
Clonal Cas9 expressing BC-3 cells were transduced with the Brunello library at ~500X
coverage and an MOI of ~0.3 and selected with puromycin as described 29 . Cells were passaged for two weeks to allow drop-out of sgRNAs targeting essential genes from the cell pool 29 . Then, cells were treated with 5µM LEN, 1µM POM, 1µM CC-122 or DMSO, in two replicates per condition. Cells were passaged every 2-3 days, while maintaining sgRNA coverage. Samples corresponding to 1000X sgRNA coverage were harvested on day 9 into POM/CC-122/DMSO or day 13 into LEN/DMSO treatment. A second sample for all conditions was taken on day 21. Preparation of genomic DNA and next generation sequencing libraries was performed as described 29 . Trimmed reads were aligned to the Brunello sgRNA library 32 using Bowtie and raw read counts were generated for each sgRNA as previously described 29 (Table S1 ). To reduce statistical noise and false positives, sgRNAs with read counts in the lowest 5% in the DMSO control were excluded from further analyses (Table S2 ). These sgRNAs include those with few copies in the library and/or those that target highly essential genes. Filtered read counts were analyzed with MAGeCK-VISPR 33 to test for enrichment of genes in treatment groups using total read normalization. sgRNA and gene level results for enrichment are in Tables S3 and S4 , respectively. Raw data are available under GEO accession number GSE122040, using reviewer token ixexicugzfkbzul).
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Cloning Lentiviral sgRNA vectors were based on pLenti-guide puro 30 (Addgene#52963), see Table S5 for sgRNA sequences and primers. For lentiviral protein expression, cDNA sequences were placed into pLC/P2Ahygro (CRBN, UBE2G1, SENP8) or pLC/P2Apuro
(CUL4A WT/K705R). Detailed cloning procedures are described in the supplemental methods. Primer sequences are listed in Table S6 and cDNA nucleotide sequences are listed in Table S7 .
Generation of cell pools by lentiviral transduction
For KO cell pools prepared for this study (CUL4A, CUL4B, UBE2G1, ILF3, YPEL5, SENP8) clonal Cas9 expressing BC-3 cells were transduced with lentiviral sgRNA vectors based on pLenti-guide puro (Addgene #52963) 34 , at an MOI of 1.5. For lentiviral protein expression, cells were transduced at an MOI <1, media were changed 24 hours after transduction, and cells were selected with hygromycin or puromycin for 5 or 3 days, respectively. Western Blot analyses were used to confirm gene inactivation or expression of the target proteins.
Cell counting, Western Blotting, and IC50 dose-response assays IC50 assays were performed as described as reported 7, 29 . Settings for primary antibodies are listed in Table S8. 7 High concentrations were chosen to assay for robust CM resistance under stringent conditions. A first sample was collected when a minimum of live cells remained: on day 14 for LEN, or day 9 for POM or CC-122 (Fig. 1C) . A second sample was harvested after a proliferating cell pool emerged under drug treatment (Fig. 1D ). The later time point was intended to assay for complete resistance, while the early time was included to detect more subtle delays in CM toxicity. sgRNA composition over two replicate screens per drug was assessed by next generation sequencing and analyzed with the MAGeCK algorithm 33, 35 .
Results
Genome
For each drug, sgRNAs targeting fewer genes were significantly enriched in the live cell population at late time points than at early time points ( Fig. 2A-F ). The number of hits furthermore decreased with increasing toxicity of the CM, such that only inactivation of CRBN appeared to confer complete resistance to CC-122 (Fig. 2F ). An enrichment for guides against CRBN was expected, because its inactivation has previously been shown to confer CM resistance in PEL 6, 7 and MM cell lines 21, 22 .
Other genes with strong sgRNA enrichments in at least a subset of settings include: the CRL4 cullin subunit CUL4B; GLMN, a previously identified binding partner of RBX1
36
; and the E2 Ub conjugating enzyme UBE2G1, which has very recently been implicated as the preferred E2 enzyme for ubiquitin chain elongation by CRL4 37, 38 . sgRNAs targeting four other genes (ILF2, ILF3, YPEL5, SENP8) were highly and specifically enriched in LENresistant cells ( , among other roles. SENP8 (also known as DEN1 or NEDP1) encodes a Nedd8-specific cysteine protease that has recently been shown to remove Nedd8 modifications from proteins other than cullins, specifically the Nedd8 conjugation machinery, including Nedd8-specific E1 and E2 enzymes 42 . While SENP8-inactivation has recently been shown to cause decreased neddylation of CUL1 and CUL5
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, SENP8
has not previously been implicated in the regulation of CRL4 activity or CM toxicity.
Both the experimental settings for our screens and cut-offs for data analyses presented in Fig. 2 were selected for high stringency. Lowering statistical cutoffs identifies additional genes as candidates for modulators of CM toxicity, among known components or regulators of CRL4, such as RBX1 and CSN subunits (see Tables S3-4 ). We note that DDB1, RBX1, and several CSN subunits are potentially essential in PEL based on our reported essentiality screens 29 ( Fig. S2) , which would prevent enrichments of sgRNAs targeting these genes in the CM resistant cell population.
Based on the prominent enrichments for CUL4B, UBE2G1, ILF2/3, YPEL5 and SENP8-specific sgRNAs, these genes were selected for further validation.
Inactivation of CUL4A or CUL4B confers resistance to lenalidomide and delays toxicity of pomalidomide
Our detection of enrichments for CUL4B sgRNAs is interesting, because it suggests that overall CUL4A and CUL4B expression levels in BC-3 cells is limiting for the efficacy of even high concentrations of CMs. To confirm this result, we transduced Cas9 expressing BC-3 cells with lentiviruses carrying two independent sgRNAs each targeting CUL4B or CUL4A, or an established negative control guide targeting the noncoding locus AAVS1. A previously reported CRBN knockout BC-3 clone served as a positive control for CM resistance 7 . Indeed, individual CRISPR/Cas9-mediated inactivation of CUL4B substantially delayed the toxicity of POM and conferred robust 9 resistance to LEN ( Fig. S3A-C) . Inactivation of CUL4A similarly conferred significant resistance to LEN, although CUL4A-specific sgRNAs were not enriched in our screens ( Fig. S3D-E ). Inactivation of CUL4A had a smaller effect on the response to POM (Fig.   S3F ). Overall, these data confirm that CUL4B and CUL4A are both expressed in PEL and contribute to CRL4 CRBN -dependent CM toxicity in BC-3. The failure for CUL4A sgRNAs to meet our statistical cutoff (Fig. 2) may reflect a relative inefficiency of these guides in the pooled approach and/or, possibly, the high stringency of the experimental setup and cutoffs.
Inactivation of UBE2G1 confers resistance to lenalidomide and pomalidomide of the more potent CC-122 but does not confer resistance against this drug (Fig. 3H, I ).
Thus, other E2 enzymes must be able to compensate for loss of UBE2G1, albeit at lower efficiency. These results parallel two recent reports 37, 43 , which similarly identified UBE2G1 as hits in genome-wide CRISPR/Cas9 screens for LEN or POM resistance in multiple myeloma. UBE2G1 was also identified as the preferred E2 in CM-induced CRL4 CRBN activity in an E2 enzyme focused CRISPR screen in multiple myeloma 38 .
Sievers et al. 37 and Lu et al. 38 confirmed a role for UBE2G1 in CM-induced toxicity in MM and proposed a "prime-extend" mechanism, whereby the E2 enzyme UBE2D3
mediates substrate mono-ubiquitination, while UBE2G1 extends the Ub chain via addition of further K48-linked Ub moieties. Inactivation of UBE2D3 alone, which did not score in our screens, did not confer significant CM resistance in PEL, suggesting the existence of redundant E2 enzymes that can fulfill this function in our system (Fig. S5) .
Overall, our data suggest a preference for CRL4 CRBN for UBE2G1, similar to that seen in multiple myeloma 37, 38, 43 .
Inactivation of SENP8 specifically confers resistance to lenalidomide
SENP8, ILF2, ILF3, and YPEL5 scored specifically for LEN but not POM or CC-122. To test effects of their inactivation on CM toxicity, we targeted each gene using two sgRNAs. Except for ILF2, where efficient inactivation was not achieved (not shown),
Western blot analyses confirmed robust target inactivation (Fig. S6A, C, 4A ).
Inactivation of ILF3 and YPEL5 modestly delayed LEN toxicity (Fig. S6B, D) , validating ILF3 and YPEL5 as modulators of CM toxicity. In contrast, inactivation of SENP8 conferred pronounced resistance to LEN (Fig. 4B) . Since SENP8 has not been implicated in CRL4 function or CM resistance to date, we decided to further investigate the role of SENP8. As predicted by the screens, inactivation of SENP8 delayed and attenuated toxicity of POM, but did not confer resistance at later time points into drug treatment (Fig. 4C) . Observed effects were specific to SENP8 inactivation, since reexpression of sgRNA resistant SENP8 restored LEN-sensitivity (Fig. 4D, E) . Western blot analyses of SENP8-inactivated BC-3 cells demonstrate rescue of IRF4 and the neosubstrates IKZF1, IKZF3 and CK1a upon treatment with LEN but not with POM ( Fig   4F, G) . Similar results were obtained in a second PEL cell line, BCBL-1, where 11 inactivation of SENP8 also conferred robust resistance to LEN and delayed the toxicity of POM (Fig. 4H-J) . Overall, these results show that inactivation of SENP8 renders cells less susceptible to LEN toxicity.
SENP8 inactivation results in accumulation of unneddylated CUL4A/B
A recent report showed that SENP8 cleaves Nedd8 from non-cullin neddylation substrates, including the Nedd8-specific E2 enzyme UBE2M and other components of the neddylation machinery 42 . Accumulation of aberrant neddylated forms of these proteins appears to render neddylation of cullins in SENP8 inactivated cells inefficient, as shown for CUL1 and CUL5 in HeLa and HEK293T cells 42 . The same study reported no effect on the neddylation status of CUL4, however. To begin to address the role of SENP8 in PEL, we probed WT and SENP8-inactivated BC-3 cells for Nedd8. As reported for 293T 42 , SENP8-inactivated BC-3 showed a depletion of unconjugated
Nedd8 and an accumulation of several Nedd8-modified proteins, presumably substrates for Nedd8 deconjugation by SENP8. In both BC-3 and BCBL-1 cells, there was an increase in the levels of unneddylated CUL4A and CUL4B (Fig. 5B-C) . Importantly, the expression of CRBN was unchanged in SENP8-inactivated cell pools (Fig. 5B) .
Therefore, the effect of SENP8 on CM efficacy is most likely at the level of reduced CUL4A/B neddylation. CUL4A/B neddylation and LEN-sensitivity in the context of SENP8 inactivation could not be restored by overexpression of either active or precursor Nedd8 (Fig. S7 ). These data suggest that the accumulation of unneddylated CUL4A/B is not a consequence of limiting pools of unconjugated Nedd8.
CRBN overexpression restores sensitivity to lenalidomide in the context of SENP8 inactivation
Because expression of Nedd8-modified CUL4A/B was not strongly reduced in the context of SENP8 inactivation, we reasoned that unneddylated CUL4A/B might dominant negatively interfere with CM toxicity. downregulation in CRBN overexpressing cells (Fig 6B) . We finally directly tested whether overexpression of non-neddylatable CUL4A K705R mutant dominant negatively interferes with CM toxicity (Fig. 6C) . While overexpression of WT CUL4A did not affect the toxicity of LEN or POM, K705R-mutant CUL4A expressing BC-3 were completely resistant to high concentrations of either LEN or POM, which formally shows that unneddylated CUL4 can drive resistance to CMs in a dominant negative manner (Fig 6D-E) .
Discussion
Here we report genome-wide CRISPR KO screens for genes whose inactivation confers resistance to three generations of CMs, i.e. LEN, POM and CC-122, in the PEL cell line BC-3. Our study confirms that CRBN is strictly required for CM toxicity. In addition, screens and validation experiments show that the E2 Ub conjugating enzyme UBE2G1 and the deneddylase SENP8 are required for optimal CM toxicity in PEL. While our work was in progress, similar screens against LEN 37 or POM 43 were reported in multiple myeloma. These screens and an additional E2-targeted CRISPR screen 38 . These groups proposed a "prime-extend" mechanism, where the E2 conjugating enzyme UBE2D3 mediates neosubstrate mono-ubiquitination, while In summary, we propose a model where overall expression levels of CRBN, CUL4A, CUL4B, UBE2G1, and SENP8 dictate sensitivity of CMs in PEL (Fig 7A-C 
